Advertisement
Advertisement
June 10, 2020
InspireMD CGuard EPS Evaluated in Published 12-Month PARADIGM Results
June 10, 2020—InspireMD, Inc. announced that 12-month results from PARADIGM study of the company’s CGuard embolic prevention system for the prevention of stroke caused by carotid artery disease were published online by Adam Mazurek, MD, et al in EuroIntervention.
According to the company, the investigators reported results of real-life patients treated with the CGuard MicroNet covered stent for carotid stenosis and the 12-month prevention of postprocedural neurologic events. The PARADIGM trial enrolled 101 unselected consecutive patients for carotid revascularization. At 30 days, only one adverse event occurred (a minor transient stroke), with no other strokes, myocardial infarctions, or deaths. No strokes occurred between 30 days and 12 months.
Piotr Musialek, MD, lead investigator of the PARADIGM study, commented in the announcement, “Our present work indicates that an effective MicroNet-covered stent protection against postprocedural neurologic events extends at least midterm in the absence of any procedure- or device-related issues.”
Advertisement
Advertisement
